Biosimilars market value could triple by 2020, says report

The market value for biosimilars around the world could reach $20 billion by the end this year and that figure could nearly triple by 2020, according to a report.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

The plausibility battleground at the EPO

9 November 2020 Plausibility in the context of the inventive step and sufficiency requirements can be a contentious issue before the European Patent Office. Markus Grammel of Grünecker reports.

Biotechnology

Association calls for more biosimilar cancer therapies in Europe

11 October 2018 Cancer biosimilars are slow to enter European drugs markets even after the branded products have gone off-patent, according to the Association of European Cancer Leagues.

Americas

US FDA approves first biosimilar, keeps quiet on naming standards

9 March 2015 The US Food and Drug Administration approved Sandoz’s cancer product Zarxio on Friday—the first biosimilar to be rubber stamped in the US.

More on this story

Europe

The plausibility battleground at the EPO

9 November 2020 Plausibility in the context of the inventive step and sufficiency requirements can be a contentious issue before the European Patent Office. Markus Grammel of Grünecker reports.

Biotechnology

Association calls for more biosimilar cancer therapies in Europe

11 October 2018 Cancer biosimilars are slow to enter European drugs markets even after the branded products have gone off-patent, according to the Association of European Cancer Leagues.

Americas

US FDA approves first biosimilar, keeps quiet on naming standards

9 March 2015 The US Food and Drug Administration approved Sandoz’s cancer product Zarxio on Friday—the first biosimilar to be rubber stamped in the US.

More on this story

Europe

The plausibility battleground at the EPO

9 November 2020 Plausibility in the context of the inventive step and sufficiency requirements can be a contentious issue before the European Patent Office. Markus Grammel of Grünecker reports.

Biotechnology

Association calls for more biosimilar cancer therapies in Europe

11 October 2018 Cancer biosimilars are slow to enter European drugs markets even after the branded products have gone off-patent, according to the Association of European Cancer Leagues.

Americas

US FDA approves first biosimilar, keeps quiet on naming standards

9 March 2015 The US Food and Drug Administration approved Sandoz’s cancer product Zarxio on Friday—the first biosimilar to be rubber stamped in the US.

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB

Biosimilars market value could triple by 2020, says report

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features